Bispecific antibodies have 2 different antigen binding specificities encoded by the variable regions of a full length IgG molecule. Merus bispecific antibodies are produced by co-transfection of individual cells with genetic constructs encoding 2 different sLC antibodies. Minimal constant region engineering ensures efficient hetero-dimerization and formation of bispecific antibodies. Through their ability to bind to 2 different epitopes on a single or multiple target antigens, bispecific antibodies can exert more potent biological activities than conventional therapeutic antibodies.
